Recent News

• 04.28.2025 - ADVANCED-2 Data Update Call
• 04.28.2025 - ADVANCED-2 Data Update Call
• 04.26.2025 - Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
• 04.26.2025 - Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
• 04.26.2025 - Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
• 04.23.2025 - Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025
• 04.23.2025 - Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025
• 04.15.2025 - George Farmer
• 04.15.2025 - George Farmer
• 04.15.2025 - Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

Recent Filings

• 04.25.2025 - DEF 14A Other definitive proxy statements
• 04.25.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.25.2025 - ARS Annual Report to Security Holders
• 04.17.2025 - 3 Initial statement of beneficial ownership of securities
• 04.17.2025 - 4 Statement of changes in beneficial ownership of securities